Trials / Completed
CompletedNCT05217082
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Health-Related Quality of Life (HRQoL) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Conditions
Timeline
- Start date
- 2022-02-22
- Primary completion
- 2022-08-03
- Completion
- 2022-08-03
- First posted
- 2022-02-01
- Last updated
- 2023-06-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05217082. Inclusion in this directory is not an endorsement.